N-Intact PTH=920 pg/ml
K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney DiseaseGUIDELINE 8. VITAMIN D THERAPY IN CKD PATIENTS8B.1 Patients treated with hemodialysis or peritoneal dialysis with serum levels of intact PTH levels >300 pg/mL (33.0 pmol/L) should receive an active vitamin D sterol (such as calcitriol, alfacalcidol, paricalcitol, or doxercalciferol; see Table 28) to reduce the serum levels of PTH to a
target range of 150 to 300 pg/mL (16.5 to 33.0 pmol/L). (EVIDENCE)
8B.1a The intermittent, intravenous administration of calcitriol is more effective than daily oral calcitriol in lowering serum PTH levels. (EVIDENCE)
8B.1b In patients with corrected serum calcium and/or phosphorus levels above the target range (see Guidelines 3 and 6, respectively), a trial of alternative vitamin D analogs, such as paricalcitol or doxercalciferol may be warranted. (OPINION)
http://www.kidney.org/professionals/kdoqi/guidelines_bone/guide8b.htm#fig12